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Summary
Background Psoriasis affects over two million people in the U.K. It has a significant
psychological and social impact on individuals and an associated high economic
cost to the U.K. National Health Service. There are many unanswered questions
about psoriasis.
Objectives To develop a protocol in order to work with patients, families, carers
and healthcare professionals to identify psoriasis uncertainties; to agree by con-
sensus a top-10 list of psoriasis uncertainties; and to disseminate prioritized
unanswered questions to researchers and funders so as to promote work that will
focus on answering the uncertainties considered most important by stakeholders.
Methods A Psoriasis Priority Setting Partnership has been established to gather
psoriasis uncertainties following the transparent methodology advocated by the
James Lind Alliance. A steering group composed of stakeholders has dissemi-
nated an initial survey to patients, families, carers and healthcare professionals
to collect information on important psoriasis questions. After removing dupli-
cations, uncertainties will be collated and checked against existing evidence to
determine whether any have already been resolved. ‘True uncertainties’ will
be circulated to stakeholders in a second survey where they will be ranked by
importance. At a final workshop, information will be distilled to generate a
top-10 list of uncertainties.
Results By following the protocol outlined in this paper a prioritized list of uncer-
tainties will be identified that will be used to inform the psoriasis research
agenda.
Conclusions Research targeted to address priorities identified by a range of stake-
holders is imperative. This project will inform policy makers and research fund-
ing bodies about what really matters to these groups.
What’s already known about this topic?
• Psoriasis is a common immune-mediated inflammatory skin disease affecting over
two million people in the U.K.
• Psoriasis has an economic cost to the U.K. National Health Service of £500 million
per annum.
• Access to appropriate care can be poor for people with psoriasis who often experi-
ence high levels of psychological distress, complex social needs and interconnected
physiological symptoms.
• Many unanswered questions about psoriasis remain.
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What does this study add?
• The Psoriasis Priority Setting Partnership is working with patients, their families,
carers and healthcare professionals to develop a protocol in order to identify uncer-
tainties about psoriasis and its management.
• A top-10 list of uncertainties will be agreed by consensus. This list will be dissem-
inated to researchers and funders to promote research on those questions that
patients, families, carers and healthcare professionals consider most important.
Psoriasis is an immune-mediated inflammatory skin disease
that affects two million people in the U.K.1,2 It has a signifi-
cant psychological and social impact on affected individuals
and costs the U.K. National Health Service at least £500 mil-
lion per annum.3 Over the past two decades an expansion in
pharmaceutical therapies for psoriasis has enhanced treatment
of the disease, particularly for more severe forms. However,
access to care that addresses the complex interlinked physio-
logical, psychological and social needs of those who have pso-
riasis is often poor.1 There remain many unmet clinical needs
and unanswered questions for psoriasis research, which, if
addressed, could improve understanding, current care and
clinical outcomes and also address the psychological and social
needs of patients.
The Psoriasis Priority Setting Partnership (PsPSP) is bringing
patients, families, carers and healthcare professionals together to
identify uncertainties about psoriasis and to prioritize, by consen-
sus, a top-10 list of these uncertainties. Here on in, patients, fami-
lies, carers and healthcare professionals will be referred to as the
‘key stakeholders’. This information will be disseminated to
researchers and research funders in order to promote research,
which will answer the questions that key stakeholders consider to
be most important. The James Lind Alliance (JLA), which is
hosted by the National Institute for Health Research, was respon-
sible for originally setting up the Priority Setting Partnership
(PSP) process and is facilitating the PsPSP process.
Materials and methods
The development of the PsPSP protocol follows the method-
ology outlined in the James Lind Alliance Guidebook.4 The PsPSP
process adopted here involves two surveys; survey 1 was com-
pleted in November 2017, and survey 2 is due to start in May
2018.
Stage one: identification and invitation of potential
partners
A number of organizations, who advocate for and represent
key stakeholders, have made a commitment to support the
PsPSP. These include the British Association of Dermatologists
(BAD), the Primary Care Dermatology Society (PCDS), the Bri-
tish Dermatology Nursing Group and the International Psoria-
sis Council.
Stage two: steering group
A strategically selected steering group comprising individuals
from across the U.K. has been convened, including seven
patient representatives and seven healthcare professionals.
The key stakeholders comprising the steering group collec-
tively represent the breadth of perspectives invested in pso-
riasis care. For example, the patient representatives are of
different ages and both sexes, with personal experience of
different types of psoriasis, psoriasis comorbidities and car-
ing for family members with the disease. The healthcare
professionals have experience in a variety of healthcare set-
tings including primary, secondary and tertiary care and
comprise a number of dermatological roles including medi-
cal, nursing and psychological. In addition, there is a PsPSP
management team based at the University of Manchester
working in close collaboration with the University of Not-
tingham’s Centre of Evidence Based Dermatology, which has
significant experience in conducting other dermatology-
focused PSPs.5–7
At our first steering group meeting, chaired by a JLA advi-
sor, the terms of reference and key milestones for the PsPSP
were agreed. The JLA advisor is a key neutral facilitator, who
ensures that the PSP process is followed in a fair, transparent
way, with equal input from key stakeholders. Detailed discus-
sion enabled the content and layout for survey 1 to be final-
ized. All steering group members completed a declaration of
interests, in order to ensure there were none that may affect
their views.
Stage three: identifying and collating uncertainties
Uncertainties about all forms of psoriasis (with the exception of
pustular disease) at all stages of life was collected from key
stakeholders. Survey 1 was a self-completion survey, and was
used to gather views, largely from the U.K. Although interna-
tional participants were permitted to complete survey 1, its
wording made it clear that it was part of a U.K. funded exercise,
wording on the survey made it clear that the survey was part of
a U.K. funded exercise and, as such, submitted questions would
only inform the research agenda in the U.K. The survey also
recorded whether the responder’s country of residence was the
U.K or elsewhere, thereby ensuring that this variable was taken
into consideration during analysis of the data.
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Participants will be asked to submit uncertainties either
online or by post in an effort to make the process as inclusive
as possible. Self-completion surveys are a good method for
data collection because it reduces social response effects,
which can occur if researchers have to be present while the
survey is completed.
The survey 1 was launched at the Annual BAD Meeting (4–
6 July 2017, Liverpool, U.K.) in partnership with the Psoriasis
Association of Great Britain, who devoted their exhibition
space to the PsPSP in order to specifically target healthcare
professionals’ responses. The Psoriasis Association, who advo-
cate for and represent patients, their families and carers, also
promoted the survey at the PCDS Autumn Meeting (21
September 2017, London, U.K.) and the Royal College of
General Practitioners Annual Conference (12–14 October
2017, Liverpool, U.K.). In addition, the Psoriasis Association
facilitated outreach to patients and their families and carers
across the U.K. Dedicated support from the Psoriasis Associa-
tion has enabled the project to overcome the challenges this
type of endeavour presents.
The PsPSP webpage, accessed via the Psoriasis Association
website, houses a link to the survey (https://www.psoriasis-
association.org.uk/research/psp); this allows data to be elec-
tronically collected and shared with the PsPSP investigator for
analysis. There are also links to the PsPSP webpage from the
webpages of the University of Manchester and the University
of Nottingham’s Centre of Evidence Based Dermatology. Sur-
vey 1 closed on 24 November 2017 after it had been deter-
mined that responses from, and outreach to, all groups had
been maximized.
Partner organizations and members of the steering group
have also taken responsibility for signposting individuals and
groups from their networks to survey 1. In order to best man-
age responses, ongoing analyses were being undertaken to
determine when theoretical saturation is approached.
Stage four: prioritization – interim priority setting
Once the ‘raw’ unanswered questions about psoriasis, identi-
fied by survey 1, have been collected and cleaned, the uncer-
tainties gathered will be assembled and analysed. This will
include content analysis of open-ended questions. Existing
sources of information, such as systematic reviews as well as
recent clinical guidelines (e.g. those from the National Insti-
tute for Health and Care Excellence and BAD), will be identi-
fied and checked by the PsPSP investigator. In conjunction
with the steering group, the PsPSP investigator will consider
to what extent the refined questions have, or have not, been
answered by previous research. In addition, a resource devel-
oped and updated monthly by the Centre of Evidence Based
Dermatology, University of Nottingham, will be used to iden-
tify relevant systematic reviews.8 This resource provides easy
access to mappings of systematic reviews by topic for a variety
of dermatological conditions and includes a psoriasis map.9
It is likely that some uncertainties will be resolved by
referring to existing research evidence, that is, they are
‘unrecognized knowns’ and not uncertainties. This informa-
tion will be a useful output of the PsPSP per se as it will
indicate to what extent existing information is not commu-
nicated effectively to those who need it. These ‘unrecog-
nized knowns’ will be shared with relevant organizations for
further dissemination so that these issues may be incorpo-
rated into the development of psoriasis information
resources.
Questions generated from survey 1 that have not been
adequately addressed by previous research will be categorized
as ‘true uncertainties’. A full list of these ‘true uncertainties’
will be collated and recorded on a template supplied by the
JLA. This data will be submitted to the JLA for publication
on its website, ensuring that the PsPSP results are publicly
available, which is in line with the principles of this
methodology.
As noted in the James Lind Alliance Guidebook,4 consensus devel-
opment and prioritization methods traditionally employed by
the Delphi technique are adapted in the interim priority set-
ting exercise. The interim stage will involve a second survey
(survey 2), which will allow the PsPSP to reduce a long list of
uncertainties to a shorter list. The steering group has agreed
that the long list of uncertainties will be composed of a maxi-
mum of 80 most frequently reported items from survey 1.
Individuals completing survey 2 will be asked to mark their
10 most important uncertainties from this list (their ‘top 10’).
As with survey 1, completion of survey 2 may be via post or
online. Individuals who have completed survey 1 and agreed
to be re-contacted by the PsPSP team will be informed of sur-
vey 2 and invited to participate.
Stage five: prioritization – final priority setting
The aim of the final priority setting stage is to prioritize,
through consensus, the identified uncertainties/specific
research questions relating to psoriasis. The 30 most fre-
quently reported items generated by survey 2 will be collated
and discussed at a priority setting workshop meeting. This will
be conducted in a face-to-face setting, using group discussions
and plenary sessions. The JLA advisor will facilitate this final
workshop where the top-10 uncertainties will be generated
from the longer list of 30. The workshop will be attended by
key stakeholders, in addition to those sitting on the PsPSP
steering group. The skilled JLA facilitators will ensure all
groups are able to contribute equally to a process that is trans-
parent and fair using an adapted nominal group technique.4 A
flowchart of the PsPSP methods is included as Figure 1.
Results
This PsPSP is working with key stakeholders, using the meth-
ods outlined in this protocol, to identify uncertainties about
psoriasis and agree on a prioritized list of top-10 uncertainties.
It is anticipated that the PsPSP will allow comment on what
key stakeholders consider to be the most important unan-
swered questions for psoriasis.
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Discussion
Recent healthcare advancements mean that some people living
with psoriasis have access to improved treatments. However,
complex unmet needs remain for people with this condition.
More targeted research is required to address these needs.
With emphasis on limited resources, it is imperative to under-
stand more comprehensively where research is most needed.
Traditionally, academic researchers and commercial interests
have had pivotal roles in setting the research agenda, with the
views of patients given little emphasis. As yet, the most
important research questions as agreed by key stakeholders are
unknown.
This PsPSP will build on previous efforts to identify gaps
and develop the research agenda in psoriasis.10–12 The most
recent work12 involved a Delphi methodology with 95
experts, most of them being clinical dermatologists. The
authors themselves identified a limitation of the work to be its
focus on clinicians. The authors suggested future work would
benefit from including the patient voice as is being done by
this PsPSP. In addition to patients, this PsPSP includes the
voice of other key stakeholders previously unrepresented in
work developing the research agenda. The JLA ensures that the
views of a multidisciplinary team of experts are heard when
developing research priorities, and this supports policy makers
and research funders in their management of scarce research
resources when prioritizing research.
The PsPSP will ensure the appropriate direction for future
psoriasis research. The top-10 list of uncertainties about
psoriasis will be disseminated to funding and research agenda
setting organizations (such as the Medical Research Council
and National Institute for Health Research) as well as the
major research funding charities (such as the Psoriasis Associa-
tion and the British Skin Foundation). By doing this, appropri-
ate research, including clinical trials, will be promoted that
will in turn transform the evidence base for psoriasis. PsPSP
outcomes will also be disseminated across local and national
patient and carer groups using the PsPSP’s networks and
Survey 1
Asked for questions regarding 
psoriasis uncertainties from patients, 
families, carers and health 
professionals
Uncertainties collated
All responses are sorted to identify 
‘true uncertainties’ and 
‘unrecognized knowns’
Survey 2
Participants in survey 2 to rank 
questions considered in 
order of importance
Top-10 uncertainties
Information will be published so that 
future research focuses on the most 
important questions
Priority setting workshop
Where top-10 uncertainties taking 
research priority will be agreed by 
patients, carers and health 
professionals
‘True uncertainties’ 
full  l ist published on
James Lind All iance
website
‘Unrecognized knowns’
shared with relevant 
organizations for further 
dissemination
Fig 1. Flowchart of Psoriasis Priority Setting Partnership protocol.
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subject knowledge. In addition, plain language press releases
and social media updates via Twitter and Facebook will be
organized.
By following the methods outlined in this protocol, this
PsPSP will provide the evidence base from which to develop
appropriate and effective evidence-based patient-facing inter-
ventions in psoriasis.
Having read this article please do look out for survey 2
which will open in May 2018:
https://www.psoriasis-association.org.uk/research/psp.
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